#pharmaceuticals - Techseriesinsight

September 18, 2025
PRNewswire
Biotechnology, Healthcare, News

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi)...

September 2, 2025
Business Wire
Biotechnology, News

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has entered into a licensing agreement for an innovative processing accelerator designed to expedite compute-intensive computations...

July 17, 2025
Business Wire
Biotechnology, News

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S....

June 17, 2025
PRNewswire
Healthcare

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy...

June 12, 2025
PRNewswire
Healthcare

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, “NRx” or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE,” or the “Company”), a multi-site clinical care delivery organization and...

May 6, 2025
PRNewswire
Biotechnology

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has...

April 17, 2025
PRNewswire
Healthcare

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new...